Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 5/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.48 |
| ▸ | PLA2G5 | P39877 | 5/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | CBLB | Q13191 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655398 | 0.81 | PLA2G2A (0.58) | PLA2G10PLA2G2APLA2G5GCGRPPARG | |
| SCHEMBL4656312 | 0.79 | ECE1 (0.55) | ECE1MAOBCHRNA7ALDH1A1NOTUM | |
| SCHEMBL3575743 | 0.78 | PLA2G10 (0.54) | PLA2G10PLA2G2APLA2G5GCGRPPARG | |
| SCHEMBL3571160 | 0.78 | ECE1 (0.48) | ECE1MAOBHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL3569792 | 0.77 | PLA2G10 (0.58) | PLA2G10ECE1MAOBPPARGTHRB | |
| SCHEMBL4655408 | 0.77 | PLA2G10 (0.48) | PLA2G10ECE1MAOBGCGRTHRB | |
| SCHEMBL4656153 | 0.75 | ECE1 (0.50) | ECE1MAOBPPARG | |
| SCHEMBL4656220 | 0.75 | ECE1 (0.59) | ECE1MAOBCHRNA7ALDH1A1NOTUM | |
| SCHEMBL4656242 | 0.74 | ECE1 (0.49) | ECE1MAOBCHRNA7THRBALDH1A1 | |
| SCHEMBL4656120 | 0.73 | ECE1 (0.50) | PLA2G10ECE1MAOBALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101010297-B | N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use | SANOFI AVENTIS | 2011-07-27 | — | — | CN | claimed |
| EP-1776340-B1 | N-(1H-INDOLYL)-H-INDOLE-2-CARB0XAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2008-12-03 | — | — | EP | claimed |
| CN-101010297-B | N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use | SANOFI AVENTIS | 2011-07-27 | — | — | CN | disclosed |
| US-7781477-B2 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| US-7582671-B2 | Therapeutic use of N-(1H-indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-09-01 | — | — | US | disclosed |
| EP-1776340-B1 | N-(1H-INDOLYL)-H-INDOLE-2-CARB0XAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2008-12-03 | — | — | EP | disclosed |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-7384969-B2 | N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| CN-101010297-A | N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use | SANOFI AVENTIS (FR) | 2007-08-01 | — | — | CN | disclosed |
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | IDO1, IDO2, NPY5R | PLA2G10 3074/4885PLA2G2A 2162/4885PLA2G5 722/4885 |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | NPY5R, TPH2, TPH1 | PLA2G10 3198/4885PLA2G2A 2484/4885PLA2G5 773/4885 |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | NPY5R, TPH2, TPH1 | PLA2G10 3198/4885PLA2G2A 2484/4885PLA2G5 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.